Literature DB >> 14599784

Vaccinology of classical swine fever: from lab to field.

J T van Oirschot1.   

Abstract

There are two types of classical swine fever vaccines available: the classical live and the recently developed E2 subunit vaccines. The live Chinese strain vaccine is the most widely used. After a single vaccination, it confers solid immunity within a few days that appears to persist lifelong. The E2 subunit vaccine induces immunity from approximately 10-14 days after a single vaccination. The immunity may persist for more than a year, but is then not complete. The Chinese strain vaccine may establish a strong herd immunity 1-2 weeks earlier than the E2 vaccine. The ability of the Chinese vaccine strain to prevent congenital infection has not been reported, but the E2 subunit vaccine does not induce complete protection against congenital infection. Immunological mechanisms that underlie the protective immunity are still to be elucidated. Both types of vaccine are considered to be safe. A great advantage of the E2 subunit vaccine is that it allows differentiation of infected pigs from vaccinated pigs and is referred to as a DIVA vaccine. However, the companion diagnostic E(rns) ELISA to actually make that differentiation should be improved. Many approaches to develop novel vaccines have been described, but none of these is likely to result in a new DIVA vaccine reaching the market in the next 5-10 years. Countries where classical swine fever is endemic can best control the infection by systematic vaccination campaigns, accompanied by the normal diagnostic procedures and control measures. Oral vaccination of wild boar may contribute to lowering the incidence of classical swine fever, and consequently diminishing the threat of virus introduction into domestic pigs. Free countries should not vaccinate and should be highly alert to rapidly diagnose any new outbreak. Once a new introduction of classical swine fever virus in dense pig areas has been confirmed, an emergency vaccination programme should be immediately instituted, for maximum benefit. The question is whether the time is ripe to seriously consider global eradication of classical swine fever virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14599784     DOI: 10.1016/j.vetmic.2003.09.008

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  45 in total

1.  Development of multiple ELISAs for the detection of antibodies against classical swine fever virus in pig sera.

Authors:  Zhen-hua Yang; Ling Li; Zi-shu Pan
Journal:  Virol Sin       Date:  2012-01-22       Impact factor: 4.327

2.  RNA Seq analysis for transcriptome profiling in response to classical swine fever vaccination in indigenous and crossbred pigs.

Authors:  Shalu Kumari Pathak; Amit Kumar; G Bhuwana; Vaishali Sah; Vikramadiya Upmanyu; A K Tiwari; A P Sahoo; A R Sahoo; Sajjad A Wani; Manjit Panigrahi; N R Sahoo; Ravi Kumar
Journal:  Funct Integr Genomics       Date:  2017-03-30       Impact factor: 3.410

3.  An outbreak of classical swine fever in pigs in Bangladesh, 2015.

Authors:  Shamim Sarkar; Mohammad Enayet Hossain; Emily S Gurley; Rashedul Hasan; Mohammed Z Rahman
Journal:  Vet Med Sci       Date:  2017-11-20

4.  Suppression of immune responses in pigs by nonstructural protein 1 of porcine reproductive and respiratory syndrome virus.

Authors:  Yefei Zhou; Juan Bai; Yufeng Li; Xinglong Wang; Xianwei Wang; Ping Jiang
Journal:  Can J Vet Res       Date:  2012-10       Impact factor: 1.310

5.  Selection of classical swine fever virus with enhanced pathogenicity reveals synergistic virulence determinants in E2 and NS4B.

Authors:  Tomokazu Tamura; Yoshihiro Sakoda; Fumi Yoshino; Takushi Nomura; Naoki Yamamoto; Yuka Sato; Masatoshi Okamatsu; Nicolas Ruggli; Hiroshi Kida
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

6.  Assessment of the phenotype and functionality of porcine CD8 T cell responses following vaccination with live attenuated classical swine fever virus (CSFV) and virulent CSFV challenge.

Authors:  Giulia Franzoni; Nitin V Kurkure; Daniel S Edgar; Helen E Everett; Wilhelm Gerner; Kikki B Bodman-Smith; Helen R Crooke; Simon P Graham
Journal:  Clin Vaccine Immunol       Date:  2013-08-21

7.  Complete genome sequence of attenuated low-temperature Thiverval strain of classical swine fever virus.

Authors:  Yunfeng Fan; Qizu Zhao; Yun Zhao; Qin Wang; Yibao Ning; Zhongqiu Zhang
Journal:  Virus Genes       Date:  2008-04-10       Impact factor: 2.332

8.  A Novel E2 Glycoprotein Subunit Marker Vaccine Produced in Plant Is Able to Prevent Classical Swine Fever Virus Vertical Transmission after Double Vaccination.

Authors:  Youngmin Park; Yeonsu Oh; Miaomiao Wang; Llilianne Ganges; José Alejandro Bohórquez; Soohong Park; Sungmin Gu; Jungae Park; Sangmin Lee; Jongkook Kim; Eunju Sohn
Journal:  Vaccines (Basel)       Date:  2021-04-22

9.  Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever.

Authors:  Tinka Jelsma; Jacob Post; Erwin van den Born; Ruud Segers; Jeroen Kortekaas
Journal:  Vaccines (Basel)       Date:  2021-05-10

10.  Generation and first characterization of TRDC-knockout pigs lacking γδ T cells.

Authors:  Bjoern Petersen; Robert Kammerer; Antje Frenzel; Petra Hassel; Tung Huy Dau; Roswitha Becker; Angele Breithaupt; Reiner Georg Ulrich; Andrea Lucas-Hahn; Gregor Meyers
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.